• Something wrong with this record ?

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR

D. Drandi, L. Kubiczkova-Besse, S. Ferrero, N. Dani, R. Passera, B. Mantoan, M. Gambella, L. Monitillo, E. Saraci, P. Ghione, E. Genuardi, D. Barbero, P. Omedè, D. Barberio, R. Hajek, U. Vitolo, A. Palumbo, S. Cortelazzo, M. Boccadoro, G....

. 2015 ; 17 (6) : 652-60. [pub] 20150828

Language English Country United States

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16028269

Real-time quantitative PCR (qPCR) is a well-established tool for minimal residual disease (MRD) detection in mature lymphoid malignancies. Despite remarkable sensitivity and specificity, qPCR has some limitations, particularly in the need for a reference standard curve, based on target serial dilutions. In this study, we established droplet digital PCR (ddPCR) for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma and compared it head-to-head with qPCR. We observed that ddPCR has sensitivity, accuracy, and reproducibility comparable with qPCR. We then compared the two approaches in 69 patients with a documented molecular marker at diagnosis (18 multiple myelomas, 21 mantle cell lymphomas assessed with the immunoglobulin gene rearrangement, and 30 follicular lymphomas with the use of the BCL2/immunoglobulin gene major breakpoint region rearrangement). ddPCR was successful in 100% of cases, whereas qPCR failed to provide a reliable standard curve in three patients. Overall, 222 of 225 samples were evaluable by both methods. The comparison highlighted a good concordance (r = 0.94, P < 0.0001) with 189 of 222 samples (85.1%; 95% CI, 80.4%-89.8%) being fully concordant. We found that ddPCR is a reliable tool for MRD detection with greater applicability and reduced labor intensiveness than qPCR. It will be necessary to authorize ddPCR as an outcome predictor tool in controlled clinical settings and multilaboratory standardization programs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028269
003      
CZ-PrNML
005      
20161031104642.0
007      
ta
008      
161005s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jmoldx.2015.05.007 $2 doi
024    7_
$a 10.1016/j.jmoldx.2015.05.007 $2 doi
035    __
$a (PubMed)26319783
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Drandi, Daniela $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy. Electronic address: daniela.drandi@unito.it.
245    10
$a Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR / $c D. Drandi, L. Kubiczkova-Besse, S. Ferrero, N. Dani, R. Passera, B. Mantoan, M. Gambella, L. Monitillo, E. Saraci, P. Ghione, E. Genuardi, D. Barbero, P. Omedè, D. Barberio, R. Hajek, U. Vitolo, A. Palumbo, S. Cortelazzo, M. Boccadoro, G. Inghirami, M. Ladetto,
520    9_
$a Real-time quantitative PCR (qPCR) is a well-established tool for minimal residual disease (MRD) detection in mature lymphoid malignancies. Despite remarkable sensitivity and specificity, qPCR has some limitations, particularly in the need for a reference standard curve, based on target serial dilutions. In this study, we established droplet digital PCR (ddPCR) for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma and compared it head-to-head with qPCR. We observed that ddPCR has sensitivity, accuracy, and reproducibility comparable with qPCR. We then compared the two approaches in 69 patients with a documented molecular marker at diagnosis (18 multiple myelomas, 21 mantle cell lymphomas assessed with the immunoglobulin gene rearrangement, and 30 follicular lymphomas with the use of the BCL2/immunoglobulin gene major breakpoint region rearrangement). ddPCR was successful in 100% of cases, whereas qPCR failed to provide a reliable standard curve in three patients. Overall, 222 of 225 samples were evaluable by both methods. The comparison highlighted a good concordance (r = 0.94, P < 0.0001) with 189 of 222 samples (85.1%; 95% CI, 80.4%-89.8%) being fully concordant. We found that ddPCR is a reliable tool for MRD detection with greater applicability and reduced labor intensiveness than qPCR. It will be necessary to authorize ddPCR as an outcome predictor tool in controlled clinical settings and multilaboratory standardization programs.
650    _2
$a lidé $7 D006801
650    _2
$a folikulární lymfom $x diagnóza $7 D008224
650    _2
$a lymfom z plášťových buněk $x diagnóza $7 D020522
650    _2
$a mnohočetný myelom $x diagnóza $7 D009101
650    _2
$a reziduální nádor $x diagnóza $7 D018365
650    _2
$a kvantitativní polymerázová řetězová reakce $x metody $7 D060888
650    _2
$a referenční standardy $7 D012015
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a senzitivita a specificita $7 D012680
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kubiczkova-Besse, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Ferrero, Simone $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Dani, Nadia $u Bioclarma srl, Torino, Italy.
700    1_
$a Passera, Roberto $u Division of Nuclear Medicine, A.O.U. Città della Salute e della Scienza, Torino, Italy.
700    1_
$a Mantoan, Barbara $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Gambella, Manuela $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Monitillo, Luigia $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Saraci, Elona $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Ghione, Paola $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Genuardi, Elisa $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Barbero, Daniela $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Omedè, Paola $u Division of Hematology, A.O.U. Città della Salute e della Scienza, Torino, Italy.
700    1_
$a Barberio, Davide $u Bioclarma srl, Torino, Italy.
700    1_
$a Hajek, Roman $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Hematooncology, Faculty of Medicine University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Vitolo, Umberto $u Division of Oncology Department, A.O.U. Città della Salute e della Scienza, Torino, Italy.
700    1_
$a Palumbo, Antonio $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Cortelazzo, Sergio $u Hematology Department, S. Maurizio Regional Hospital, Bolzano, Italy.
700    1_
$a Boccadoro, Mario $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Inghirami, Giorgio $u Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Cornell Medical Center, New York, New York; Division of Pathology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
700    1_
$a Ladetto, Marco $u Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy; Hematology Division, A.O.S. Antonio, Biagio and Cesare Arrigo, Alessandria, Italy.
773    0_
$w MED00012712 $t The Journal of molecular diagnostics JMD $x 1943-7811 $g Roč. 17, č. 6 (2015), s. 652-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26319783 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161031105103 $b ABA008
999    __
$a ok $b bmc $g 1166583 $s 952899
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 17 $c 6 $d 652-60 $e 20150828 $i 1943-7811 $m The Journal of molecular diagnostics $n J Mol Diagn $x MED00012712
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options